Anti-amyloids are the recent hope and promise in AD treatment. They work by attaching to and removing a protein that accumulates into plaques, β-amyloid, from the brain. These monoclonal antibody drugs target β-amyloid at a different stage of plaque formation (Figure ). However, the results of the ongoing clinical trials are still controversial, and for the time being the benefits of these drugs seem to be harder to quantify than potential harms. • Aducanumab (Aduhelm) is an anti-amyloid antibody, which received accelerated FDA approval for treatment of early AD in 2021. It has been the first medication to demonstrate that removing β-amyloid from the brain reduces cognitive and functional decline. Aducanumab is being discontinued by its manufacturer, Biogen. The company stated that this decision is not related to any safety or efficacy concerns. • Lecanemab (Leqembi) is an anti-amyloid antibody, which received traditional FDA approval for treatment of early AD. It is the second therapy to demonstrate that removing β-amyloid from the brain reduces cognitive and functional decline in patients living with early AD and the first to show clinical benefits. • Donanemab is an anti-amyloid antibody, currently under FDA review for approval, as a possible treatment for AD. Application for full FDA approval initially took place in 2023 with the FDA delaying approval evaluation until later in 2024. It targets β-amyloid plaque, potentially reducing the excess protein reducing cognitive and functional decline. Figure . Scheme of the formation of amyloid plaques and target sites of the anti-amyloid antibody drugs (Adapted from "Cleavage of Amyloid Precursor Protein", by BioRender.com (2024). Retrieved from ).